PubMed · 1982 · 31 citations · 0 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyHepatic PharmacokineticsDrug DispositionReproductive PharmacologySteroid PharmacologyDaily DosingEstrogen PharmacologyHormonal Contraceptive PharmacologyOral Contraceptive EffectsOral Contraceptive InteractionsPharmacokinetic ParametersPharmacokinetics Of Hormonal ContraceptivesPharmacokinetics Of Reproductive Hormones
During the past 25 years over 50 million women have used oral contraceptives (OCs) and have been exposed to the actions of ethinyl estradiol (EE) or its 3-methylether, mestranol, usually at the dosage of 50 mcg/day. EE is rapidly absorbed but not all of it becomes bioavailable due to exclusive metabolism in the intestinal wall and liver. Within 1 hour of administration a major proportion of the dose of EE was conjugated or metabolized. Also discussed in this paper are protein binding of EE, tissue distribution, and interaction with other drugs. Regarding EE in the blood the author describes unconjugated and conjugated EE. Pharmacokinetic studies carried out indicate that sulphate acts as a reservoir or slow release form for unconjugated and biologically active EE. There is a significant correlation between peak blood levels attained and the area under the curve. Wide variations such as the 10-fold variation in bioavailability and elimination rate may have important consequences, particularly with the reduction during the past few years in the daily dose of OCs. In women with a low bioavailability and short half-life for the steroid, its efficacy may be reduced and if not sufficiently to lose contraception value it may result in an increase in other side effects such as spotting. Also women with high bioavailability might be expected to manifest other side effects.